Interleukin-1β, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome

Joseph Gerard Cannon, Jonathan B. Angel, Leslie W. Abad, Edouard Vannier, Maria D. Mileno, Laura Fagioli, Sheldon M. Wolff, Anthony L. Komaroff

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Chronic fatigue syndrome is a condition that affects women in disproportionate numbers, and that is often exacerbated in the premenstrual period and following physical exertion. The signs and symptoms which include fatigue, myalgia, and low-grade fever, are similar to those experienced by patients infused with cytokines such as interleukin-I. The present study was carried out to test the hypotheses that (1) cellular secretion of interleukin-1β (IL-1β), interleukin-1 receptor antagonist (IL-1Ra), and soluble interleukin-1 receptor type II (IL-1sRII) is abnormal in female CFS patients compared to age- and activity-matched controls; (2) that these abnormalities may be evident only at certain times in the menstrual cycle; and (3) that physical exertion (stepping up and down on a platform for 15 min) may accentuate differences between these groups. Isolated peripheral blood mononuclear cells from healthy women, but not CFS patients, exhibited significant menstrual cycle-related differences in IL-1β secretion that were related to estradiol and progesterone levels (R2 = 0.65, P < 0.01). IL- 1Ra secretion for CFS patients was twofold higher than controls during the follicular phase (P = 0.023), but lutea]-phase levels were similar between groups. In both phases of the menstrual cycle, IL-1sRII release was significantly higher for CFS patients compared to controls (P = 0.0002). The only changes that might be attributable to exertion occurred in the control subjects during the follicular phase, who exhibited an increase in IL-1β secretion 48 hr after the stress (P = 0.020). These results suggest that an abnormality exists in IL 1β secretion in CFS patients that may be related to altered sensitivity to estradiol and progesterone. Furthermore, the increased release of IL-1Ra and sIL-1RII by cells from CFS patients is consistent with the hypothesis that CFS is associated with chronic, low-level activation of the immune system.

Original languageEnglish (US)
Pages (from-to)253-261
Number of pages9
JournalJournal of Clinical Immunology
Volume17
Issue number3
DOIs
StatePublished - Jul 3 1997

Fingerprint

Interleukin-1 Type II Receptors
Chronic Fatigue Syndrome
Interleukin-1 Receptors
Interleukin-1
Menstrual Cycle
Interleukin 1 Receptor Antagonist Protein
Physical Exertion
Follicular Phase
Progesterone
Estradiol
Myalgia
Signs and Symptoms
Fatigue
Immune System
Blood Cells
Fever
Cytokines

Keywords

  • Menstrual cycle
  • chronic fatigue syndrome
  • estradiol
  • interleukin-1
  • progestorone

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Interleukin-1β, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome. / Cannon, Joseph Gerard; Angel, Jonathan B.; Abad, Leslie W.; Vannier, Edouard; Mileno, Maria D.; Fagioli, Laura; Wolff, Sheldon M.; Komaroff, Anthony L.

In: Journal of Clinical Immunology, Vol. 17, No. 3, 03.07.1997, p. 253-261.

Research output: Contribution to journalArticle

Cannon, JG, Angel, JB, Abad, LW, Vannier, E, Mileno, MD, Fagioli, L, Wolff, SM & Komaroff, AL 1997, 'Interleukin-1β, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome', Journal of Clinical Immunology, vol. 17, no. 3, pp. 253-261. https://doi.org/10.1023/A:1027314713231
Cannon, Joseph Gerard ; Angel, Jonathan B. ; Abad, Leslie W. ; Vannier, Edouard ; Mileno, Maria D. ; Fagioli, Laura ; Wolff, Sheldon M. ; Komaroff, Anthony L. / Interleukin-1β, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome. In: Journal of Clinical Immunology. 1997 ; Vol. 17, No. 3. pp. 253-261.
@article{23b519f0cf48472fb9d9eb099a5ef4f2,
title = "Interleukin-1β, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome",
abstract = "Chronic fatigue syndrome is a condition that affects women in disproportionate numbers, and that is often exacerbated in the premenstrual period and following physical exertion. The signs and symptoms which include fatigue, myalgia, and low-grade fever, are similar to those experienced by patients infused with cytokines such as interleukin-I. The present study was carried out to test the hypotheses that (1) cellular secretion of interleukin-1β (IL-1β), interleukin-1 receptor antagonist (IL-1Ra), and soluble interleukin-1 receptor type II (IL-1sRII) is abnormal in female CFS patients compared to age- and activity-matched controls; (2) that these abnormalities may be evident only at certain times in the menstrual cycle; and (3) that physical exertion (stepping up and down on a platform for 15 min) may accentuate differences between these groups. Isolated peripheral blood mononuclear cells from healthy women, but not CFS patients, exhibited significant menstrual cycle-related differences in IL-1β secretion that were related to estradiol and progesterone levels (R2 = 0.65, P < 0.01). IL- 1Ra secretion for CFS patients was twofold higher than controls during the follicular phase (P = 0.023), but lutea]-phase levels were similar between groups. In both phases of the menstrual cycle, IL-1sRII release was significantly higher for CFS patients compared to controls (P = 0.0002). The only changes that might be attributable to exertion occurred in the control subjects during the follicular phase, who exhibited an increase in IL-1β secretion 48 hr after the stress (P = 0.020). These results suggest that an abnormality exists in IL 1β secretion in CFS patients that may be related to altered sensitivity to estradiol and progesterone. Furthermore, the increased release of IL-1Ra and sIL-1RII by cells from CFS patients is consistent with the hypothesis that CFS is associated with chronic, low-level activation of the immune system.",
keywords = "Menstrual cycle, chronic fatigue syndrome, estradiol, interleukin-1, progestorone",
author = "Cannon, {Joseph Gerard} and Angel, {Jonathan B.} and Abad, {Leslie W.} and Edouard Vannier and Mileno, {Maria D.} and Laura Fagioli and Wolff, {Sheldon M.} and Komaroff, {Anthony L.}",
year = "1997",
month = "7",
day = "3",
doi = "10.1023/A:1027314713231",
language = "English (US)",
volume = "17",
pages = "253--261",
journal = "Journal of Clinical Immunology",
issn = "0271-9142",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Interleukin-1β, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome

AU - Cannon, Joseph Gerard

AU - Angel, Jonathan B.

AU - Abad, Leslie W.

AU - Vannier, Edouard

AU - Mileno, Maria D.

AU - Fagioli, Laura

AU - Wolff, Sheldon M.

AU - Komaroff, Anthony L.

PY - 1997/7/3

Y1 - 1997/7/3

N2 - Chronic fatigue syndrome is a condition that affects women in disproportionate numbers, and that is often exacerbated in the premenstrual period and following physical exertion. The signs and symptoms which include fatigue, myalgia, and low-grade fever, are similar to those experienced by patients infused with cytokines such as interleukin-I. The present study was carried out to test the hypotheses that (1) cellular secretion of interleukin-1β (IL-1β), interleukin-1 receptor antagonist (IL-1Ra), and soluble interleukin-1 receptor type II (IL-1sRII) is abnormal in female CFS patients compared to age- and activity-matched controls; (2) that these abnormalities may be evident only at certain times in the menstrual cycle; and (3) that physical exertion (stepping up and down on a platform for 15 min) may accentuate differences between these groups. Isolated peripheral blood mononuclear cells from healthy women, but not CFS patients, exhibited significant menstrual cycle-related differences in IL-1β secretion that were related to estradiol and progesterone levels (R2 = 0.65, P < 0.01). IL- 1Ra secretion for CFS patients was twofold higher than controls during the follicular phase (P = 0.023), but lutea]-phase levels were similar between groups. In both phases of the menstrual cycle, IL-1sRII release was significantly higher for CFS patients compared to controls (P = 0.0002). The only changes that might be attributable to exertion occurred in the control subjects during the follicular phase, who exhibited an increase in IL-1β secretion 48 hr after the stress (P = 0.020). These results suggest that an abnormality exists in IL 1β secretion in CFS patients that may be related to altered sensitivity to estradiol and progesterone. Furthermore, the increased release of IL-1Ra and sIL-1RII by cells from CFS patients is consistent with the hypothesis that CFS is associated with chronic, low-level activation of the immune system.

AB - Chronic fatigue syndrome is a condition that affects women in disproportionate numbers, and that is often exacerbated in the premenstrual period and following physical exertion. The signs and symptoms which include fatigue, myalgia, and low-grade fever, are similar to those experienced by patients infused with cytokines such as interleukin-I. The present study was carried out to test the hypotheses that (1) cellular secretion of interleukin-1β (IL-1β), interleukin-1 receptor antagonist (IL-1Ra), and soluble interleukin-1 receptor type II (IL-1sRII) is abnormal in female CFS patients compared to age- and activity-matched controls; (2) that these abnormalities may be evident only at certain times in the menstrual cycle; and (3) that physical exertion (stepping up and down on a platform for 15 min) may accentuate differences between these groups. Isolated peripheral blood mononuclear cells from healthy women, but not CFS patients, exhibited significant menstrual cycle-related differences in IL-1β secretion that were related to estradiol and progesterone levels (R2 = 0.65, P < 0.01). IL- 1Ra secretion for CFS patients was twofold higher than controls during the follicular phase (P = 0.023), but lutea]-phase levels were similar between groups. In both phases of the menstrual cycle, IL-1sRII release was significantly higher for CFS patients compared to controls (P = 0.0002). The only changes that might be attributable to exertion occurred in the control subjects during the follicular phase, who exhibited an increase in IL-1β secretion 48 hr after the stress (P = 0.020). These results suggest that an abnormality exists in IL 1β secretion in CFS patients that may be related to altered sensitivity to estradiol and progesterone. Furthermore, the increased release of IL-1Ra and sIL-1RII by cells from CFS patients is consistent with the hypothesis that CFS is associated with chronic, low-level activation of the immune system.

KW - Menstrual cycle

KW - chronic fatigue syndrome

KW - estradiol

KW - interleukin-1

KW - progestorone

UR - http://www.scopus.com/inward/record.url?scp=0030938643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030938643&partnerID=8YFLogxK

U2 - 10.1023/A:1027314713231

DO - 10.1023/A:1027314713231

M3 - Article

VL - 17

SP - 253

EP - 261

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

SN - 0271-9142

IS - 3

ER -